Date: October 12, 2021
Your Name: Maotao Du

Manuscript Title: <u>Aloe-emodin inhibits the proliferation, migration, and invasion of melanoma cells via</u> inactivation of the Wnt/beta-catenin signaling pathway

Manuscript number (if known): None

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | XNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | XNone | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | XNone | |
| | | | |
| | | | |
| 4 | Consulting fees | XNone | |
| | | | |
| | | | |
| 5 | Payment or honoraria for | X None | |

| | lectures, presentations, speakers bureaus, manuscript writing or educational events | | |
|-----|---|-------------------------------|-------------|
| 6 | Payment for expert | XNone | |
| | testimony | | |
| 7 | Support for attending meetings and/or travel | XNone | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| 9 | Participation on a Data | X None | |
| 9 | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| 12 | Descipt of annique and | V. Nana | |
| 12 | Receipt of equipment, materials, drugs, medical | XNone | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- financial interests | XNone | |
| | inanciai interests | | |
| | | | |
| | | | |
| Ple | ease summarize the above c | onflict of interest in the fo | lowing box: |

| The authors have no conflicts of interest to declare. |
|---|
| |
| |
| |

Date: October 12, 2021 **Your Name:** Pan Shen

Manuscript Title: <u>Aloe-emodin inhibits the proliferation, migration, and invasion of melanoma cells via</u> inactivation of the Wnt/beta-catenin signaling pathway

Manuscript number (if known): None

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | XNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | XNone | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | XNone | |
| | | | |
| | | | |
| 4 | Consulting fees | XNone | |
| | | | |
| | | | |
| 5 | Payment or honoraria for | X None | |

| | lectures, presentations, speakers bureaus, manuscript writing or educational events | | |
|-----|---|-------------------------------|-------------|
| 6 | Payment for expert | XNone | |
| | testimony | | |
| 7 | Support for attending meetings and/or travel | XNone | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| 9 | Participation on a Data | X None | |
| 9 | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| 12 | Descipt of annique and | V. Nana | |
| 12 | Receipt of equipment, materials, drugs, medical | XNone | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- financial interests | XNone | |
| | inanciai interests | | |
| | | | |
| | | | |
| Ple | ease summarize the above c | onflict of interest in the fo | lowing box: |

| The authors have no conflicts of interest to declare. |
|---|
| |
| |
| |

Date: October12, 2021
Your Name: Ranjing Tan

Manuscript Title: <u>Aloe-emodin inhibits the proliferation, migration, and invasion of melanoma cells via</u> inactivation of the Wnt/beta-catenin signaling pathway

Manuscript number (if known): None

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | X_None | |
| 5 | Payment or honoraria for | XNone | |

| | lectures, presentations, speakers bureaus, manuscript writing or educational events | | |
|-----|---|-------------------------------|-------------|
| 6 | Payment for expert | XNone | |
| | testimony | | |
| 7 | Support for attending meetings and/or travel | XNone | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| 9 | Participation on a Data | X None | |
| 9 | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| 12 | Descipt of annique and | V. Nana | |
| 12 | Receipt of equipment, materials, drugs, medical | XNone | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- financial interests | XNone | |
| | inanciai interests | | |
| | | | |
| | | | |
| Ple | ease summarize the above c | onflict of interest in the fo | lowing box: |

| The authors have no conflicts of interest to declare. |
|---|
| |
| |
| |

Date: October 12, 2021
Your Name: Dengyan Wu

Manuscript Title: <u>Aloe-emodin inhibits the proliferation, migration, and invasion of melanoma cells via</u> inactivation of the Wnt/beta-catenin signaling pathway

Manuscript number (if known): None

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | X_None | |
| 5 | Payment or honoraria for | XNone | |

| | lectures, presentations, speakers bureaus, manuscript writing or educational events | | |
|-----|---|-------------------------------|-------------|
| 6 | Payment for expert | XNone | |
| | testimony | | |
| 7 | Support for attending meetings and/or travel | XNone | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| 9 | Participation on a Data | X None | |
| 9 | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| 12 | Descipt of annique and | V. Nana | |
| 12 | Receipt of equipment, materials, drugs, medical | XNone | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- financial interests | XNone | |
| | inanciai interests | | |
| | | | |
| | | | |
| Ple | ease summarize the above c | onflict of interest in the fo | lowing box: |

| The authors have no conflicts of interest to declare. |
|---|
| |
| |
| |

Date: October 12, 2021
Your Name: Shenghao Tu

Manuscript Title: <u>Aloe-emodin inhibits the proliferation, migration, and invasion of melanoma cells via</u> inactivation of the Wnt/beta-catenin signaling pathway

Manuscript number (if known): None

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, | XNone | |
| | provision of study materials, medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | XNone | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | XNone | |
| | | | |
| | | | |
| 4 | Consulting fees | XNone | |
| | | | |
| | | | |
| 5 | Payment or honoraria for | X None | |

| | lectures, presentations, speakers bureaus, manuscript writing or educational events | | | | | |
|-----|---|-------------------------------|-------------|--|--|--|
| 6 | Payment for expert | XNone | | | | |
| | testimony | | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | | |
| | | | | | | |
| | | | | | | |
| 8 | Patents planned, issued or | XNone | | | | |
| | pending | | | | | |
| 9 | Participation on a Data | X None | | | | |
| 9 | Safety Monitoring Board or | | | | | |
| | Advisory Board | | | | | |
| 10 | Leadership or fiduciary role | XNone | | | | |
| | in other board, society, | | | | | |
| | committee or advocacy group, paid or unpaid | | | | | |
| 11 | Stock or stock options | XNone | | | | |
| | | | | | | |
| 12 | Descipt of annique and | V. Nana | | | | |
| 12 | Receipt of equipment, materials, drugs, medical | XNone | | | | |
| | writing, gifts or other | | | | | |
| | services | | | | | |
| 13 | Other financial or non- financial interests | XNone | | | | |
| | inanciai interests | | | | | |
| | | | | | | |
| | | | | | | |
| Ple | ease summarize the above c | onflict of interest in the fo | lowing box: | | | |

| The authors have no conflicts of interest to declare. | | |
|---|--|--|
| | | |
| | | |
| | | |